Holding(s) in Company

January 7, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Shire Plc
JE00B2QKY057
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuerX
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights 
An acquisition or disposal of financial instrumentsX
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameUBS Investment Bank
UBS Group AG
City and country of registered office (if applicable)Zürich
Switzerland
4. Full name of shareholder(s) (if different from 3.)v
NameUBS AG London Branch
City and country of registered office (if applicable)London, United Kingdom
5. Date on which the threshold was crossed or reachedvi:3 January 2019
6. Date on which issuer notified (DD/MM/YYYY):7 January 2019
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached6.80%0.78%7.58%918,120,398 
Position of previous notification (if
applicable)
6.86%2.23%9.10% 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
JE00B2QKY057 62'432'281 6.80%
     
     
SUBTOTAL 8. A62'432'2816.80%
 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
Right to recall lent ADRs (US82481R1068) Anytime396'0000.04%
US82481R1068  5'174'3700.56%
Physically settled Long Call Options18/01/2019 to 18/04/2019 933'0000.10%
  SUBTOTAL 8. B 16'503'3700.71%
 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
Short Put  Options18/01/2019 Physical658'8000.07%
      
      
   SUBTOTAL 8.B.2658'8000.07%
 


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
UBS Group AG   
UBS AG   
UBS AG London Branch6.80% 7.58%
    
UBS Group AG   
UBS AG   
UBS Limited   
    
UBS Group AG   
UBS AG   
UBS Switzerland AG   
    
UBS Group AG   
UBS AG   
UBS Americas Holding LLC   
UBS Americas Inc.   
UBS Securities LLC   


 

 

 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
 


Place of completionOpfikon, Switzerland
Date of completion07.01.2019

For further information please contact:

Investor Relations  
Christoph Brackmannchristoph.brackmann@shire.com+41 41 288 41 29
Sun Kimsun.kim@shire.com+1 617 588 8175
Scott Burrowsscott.burrows@shire.com+41 41 288 4195
   
Media  
Katie Joycekjoyce@shire.com +1 781 482 2779
   

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
 
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com